Evommune (EVMN)
Develops chronic-inflammation therapies centered on EVO756 and EVO301 clinical programs.
$9.70
After-hours close+0.11 (+1.15%)
At close$9.59(+1.48%)
In millions of USD, except per-share figures
| In millions | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7 | 0 | 0 | 3 | 0 | 10 | 0 | 0 | 0 |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 7 | 0 | 0 | 3 | 0 | 10 | 0 | 0 | 0 |
| 10 | 28 | 19 | 18 | 23 | 23 | 30 | 24 | 35 | |
| Research & development | 8 | 25 | 16 | 14 | 20 | 20 | 20 | 17 | 26 |
| 3 | 3 | 3 | 3 | 3 | 4 | 9 | 6 | 8 | |
| Selling & marketing | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 |
| General & administrative | 0 | 0 | 2 | 0 | 3 | 4 | 7 | 0 | 8 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −4 | −28 | −19 | −15 | −23 | −13 | −30 | −24 | −35 |
| 1 | 1 | 1 | 0 | 9 | 1 | 1 | 2 | 3 | |
| Interest income | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 3 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | −1 | −1 | −1 | 0 | −9 | −1 | −1 | −2 | 0 |
| Income before tax | −3 | −27 | −18 | −15 | −14 | −12 | −28 | −22 | −32 |
| Net income from continuing operations | −3 | −27 | −18 | −15 | −14 | −12 | −28 | −22 | −32 |
| Net income | −3 | −27 | −18 | −15 | −14 | −12 | −28 | −22 | −32 |
| EPS, basic | −$0.09 | −$0.91 | −$0.63 | −$0.48 | −$0.45 | −$0.40 | −$0.90 | −$0.64 | −$0.89 |
| EPS, diluted | −$0.09 | −$0.91 | −$0.63 | −$0.48 | −$0.45 | −$0.40 | −$0.90 | −$0.64 | −$0.89 |
| Weighted average shares, basic | 30 | 30 | 30 | 30 | 30 | 32 | 32 | 34 | 36 |
| Weighted average shares, diluted | 30 | 30 | 30 | 30 | 30 | 32 | 32 | 34 | 36 |
| EBITDA | −3 | −27 | −18 | −14 | −13 | −12 | −28 | −21 | −34 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| EBIT | −3 | −27 | −18 | −15 | −14 | −12 | −28 | −22 | −35 |